GRS News

It’s coming home

It’s coming home

It’s coming home

The cheers echoed across the country when the England football team won the semi-finals against the Netherlands during the Euros Cup.

 

While we hope and pray that it officially is ‘Coming Home’, our team want to highlight the success of what actually has ‘Come Home’ and how ‘Home’ is supporting the mission!

 

The UK's life sciences industry has demonstrated remarkable resilience despite facing numerous regulatory challenges and trade policy changes in recent years. This adaptability has allowed the UK to maintain its status as a global leader in the sector, particularly in patient care and safety. This resilience not only underscores the industry's adaptability but also its critical role in both local and international markets.

 

The UK's life sciences industry is a cornerstone of its economy, contributing a substantial £43.3 billion in Gross Value Added (GVA). Pharmaceutical manufacturing alone accounts for £19.2 billion of this total, underscoring the sector's significant economic impact​ (PwC)​. This robust contribution demonstrates the strength and importance of life sciences within the UK’s economic framework.

 

Trade remains a crucial component of the UK's life sciences sector. In 2021, the UK exported life sciences products worth £31.8 billion and imported goods valued at £27.5 billion​ (GOV.UK)​. These figures not only reflect the UK's solid global trading position but also its ability to attract and sustain international business partnerships despite regulatory and market pressures. The industry is recognised for its world-leading research and development capabilities, which are driven by substantial investments and a supportive ecosystem. The sector's innovative strength is reflected in the diversity of its contributions, ranging from pharmaceuticals to medical technologies and biotechnologies.

 

The UK’s ability to foster a thriving environment for life sciences is further demonstrated by significant foreign direct investment (FDI). In 2022, the UK attracted an estimated £1 billion in inward FDI for life sciences despite a challenging global investment climate​ (GOV.UK)​. This investment is a testament to the UK's enduring appeal as a hub for scientific innovation and business growth.

 

How is all of this possible? The role of UK’s Life Science ecosystem.

 

This is possible because of the strong players in the life science ecosystem. From the very top to the grassroots level, the UK has a robust ecosystem where organisations and companies like Innovate UK, the Department of Business and Trade, University Knowledge Transfer offices, Health Innovation Networks and a large pool of talented innovators work in tandem with several service providers who support each other in overcoming several barriers to innovation.

Our company, Global Regulatory Services [GRS], has been a supportive member and player of this ecosystem. The life sciences industry has voiced concerns over uncertain regulatory requirements and unfavourable market conditions, which have posed significant challenges. These include navigating post-Brexit regulatory landscapes, adapting to new compliance standards, and overcoming hurdles in international trade. This is where our regulatory experts have always supported in holding the fort.

 

Since 2007, Global Regulatory Services [GRS] has worked with companies of all sizes and supported them at different stages of product development, aiming to make these companies a market success. While our regular services of Quality Management Systems, GMP, and Regulatory reports continue, today we would like to highlight our:

 

UK – Responsible Person services.

We offer our UK RP services to support international life science companies selling their products in the UK markets. This helps international manufacturers comply with local UK regulatory requirements, which a collaborative team of experts addresses. Read more about our UK RP Services by clicking on this hyperlink text.

 

In order to support our UK clients, GRS took a step and spun-out Med-Di-Dia.

 

Med-Di-Dia is your Regulatory Risk Partner for Medical Devices, Diagnostics and Digital Health!
In the Euros (football tournament) context, Med-Di-Dia is your EU Authorised Representative [EUAR].

 

Crème de la Crème - Health and Beauty Cosmetics Regulatory and Quality Compliance Consultancy 

 

In continued efforts to support companies at ‘home’ and abroad, Global Regulatory Services [GRS] has an extended arm known as Crème de la Crème, which supports health and beauty cosmetics companies in complying with Regulatory and Quality compliance requirements in the UK, USA, India, EU, and beyond. Visit our website by clicking on this hyperlink text.

 

From Medicinal Cannabis, MedTech, BioTech, and Pharma to Health and Beauty Cosmetics, we are here - Driving innovation to market success™

 

Despite the challenges and global economic conditions, the UK has shown remarkable resilience, continuously adapting to maintain its competitive edge. We hope our team at the Euros does the same and brings it home! While we can only cheer for the football team, GRS continues to support the Life science Industry with Regulatory and Quality Compliance requirements. Reach out to us via email – at grs@globalregulatoryservices.com or submit a web form by visiting - https://globalregulatoryservices.com/global-regulatory-services-contact-details